Trentment of non-transplant eligible patients

被引:0
|
作者
Weisel, K. C. [1 ]
机构
[1] Univ Hosp Tubingen, Dept Hematol & Oncol, Tubingen, Germany
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
V427
引用
收藏
页码:116 / 116
页数:1
相关论文
共 50 条
  • [1] The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
    Bobin, Arthur
    Gardeney, Helene
    Sabirou, Florence
    Gruchet, Cecile
    Levy, Anthony
    Nsiala, Laly
    Cailly, Laura
    Tomowiak, Cecile
    Torregrosa, Jose
    Guidez, Stephanie
    Leleu, Xavier
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [2] Absolute Lymphocyte Count and Immunoparesis: Impact on Clinical Outcomes for Non-transplant Eligible MM Patients
    Jimenez-Zepeda, Victor
    Duggan, Peter
    Neri, Paola
    Tay, Jason
    Bahlis, Nizar J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E114 - E115
  • [3] Targeted and cytotoxic therapies as maintenance treatment for non-transplant eligible patients with acute myeloid leukemia
    Patel, Shyam A.
    Litzow, Mark R.
    Cerny, Jan
    BLOOD REVIEWS, 2021, 50
  • [4] How First-Line Therapy is Changing in non-Transplant Eligible Multiple Myeloma Patients
    Fazio, Francesca
    Deiana, Luca
    Loi, Cristian
    Mura, Francesca
    Petrucci, Maria Teresa
    Derudas, Daniele
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2025, 17 (01)
  • [5] Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
    Bobin, Arthur
    Kyheng, Maeva
    Guidez, Stephanie
    Gruchet-Merouze, Cecile
    Richez, Valentine
    Duhamel, Alain
    Karlin, Lionel
    Kolb, Brigitte
    Tiab, Mourad
    Araujo, Carla
    Meuleman, Nathalie
    Malfuson, Jean-Valere
    Bourquard, Pascal
    Lenain, Pascal
    Perrot, Aurore
    Roussel, Murielle
    Jaccard, Arnaud
    Petillon, Marie-Odile
    Belhadj-Merzoug, Karim
    Chretien, Marie-Lorraine
    Fontan, Jean
    Rodon, Philippe
    Schmitt, Anna
    Offner, Fritz
    Voillat, Laurent
    Cereja, Sophie
    Kuhnowski, Frederique
    Rigaudeau, Sophie
    Decaux, Olivier
    Humbrecht-Kraut, Catherine
    Frayfer, Jamile
    Fitoussi, Olivier
    Roos-Weil, Damien
    Eisenmann, Jean Claude
    Dorvaux, Veronique
    Voog, Eric G.
    Moreau, Philippe
    Avet-Loiseau, Herve
    Hulin, Cyrille
    Facon, Thierry
    Leleu, Xavier
    LEUKEMIA, 2022, 36 (03) : 881 - 884
  • [6] Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
    Arthur Bobin
    Maéva Kyheng
    Stéphanie Guidez
    Cécile Gruchet-Merouze
    Valentine Richez
    Alain Duhamel
    Lionel Karlin
    Brigitte Kolb
    Mourad Tiab
    Carla Araujo
    Nathalie Meuleman
    Jean-Valère Malfuson
    Pascal Bourquard
    Pascal Lenain
    Aurore Perrot
    Murielle Roussel
    Arnaud Jaccard
    Marie-Odile Petillon
    Karim Belhadj-Merzoug
    Marie-Lorraine Chretien
    Jean Fontan
    Philippe Rodon
    Anna Schmitt
    Fritz Offner
    Laurent Voillat
    Sophie Cereja
    Frédérique Kuhnowski
    Sophie Rigaudeau
    Olivier Decaux
    Catherine Humbrecht-Kraut
    Jamile Frayfer
    Olivier Fitoussi
    Damien Roos-Weil
    Jean Claude Eisenmann
    Véronique Dorvaux
    Eric G. Voog
    Philippe Moreau
    Hervé Avet-Loiseau
    Cyrille Hulin
    Thierry Facon
    Xavier Leleu
    Leukemia, 2022, 36 : 881 - 884
  • [8] Non-transplant eligible multiple myeloma: deciphering optimal first line regimens
    Vaxman, Iuliana
    Gertz, Morie
    LEUKEMIA & LYMPHOMA, 2020, 61 (03) : 504 - 506
  • [9] Cyclophosphamide, Bortezomib and Dexamethasone (CyBORD) Is a Feasible and Active Regimen for Non-Transplant Eligible Multiple Myeloma Patients
    Zepeda, Victor H. Jimenez
    Duggan, Peter
    Neri, Paola E.
    Bahlis, Nizar J.
    BLOOD, 2014, 124 (21)
  • [10] Transplant and non-transplant HCC patients at a single institution
    Carr, Brian I.
    Bag, Harika
    Ince, Volkan
    Isik, Burak
    Baskiran, Adil
    Yilmaz, Sezai
    HEPATOLOGY FORUM, 2024, 5 (02): : 77 - 86